Avanos Medical Reports Q4 & Full-Year 2025 Results, Exceeds Revenue & EPS Guidance, Issues 2026 Outlook

summarizeSummary

Avanos Medical, Inc. reported its fourth quarter and full-year 2025 financial results, notably exceeding full-year revenue and achieving the top end of its full-year adjusted earnings-per-share guidance. This performance, following the 2025 estimates provided in January, demonstrates the company's ability to meet its internal targets. While adjusted operating profit and EBITDA for the full year 2025 were lower compared to 2024, the company made significant progress in reducing its net debt and advancing transformation initiatives expected to yield substantial annualized savings by the end of 2026. The 2026 outlook projects relatively stable net sales and adjusted diluted EPS, indicating a focus on consistent performance and operational efficiency rather than aggressive growth.

check_boxKey Events

• Exceeded 2025 Full-Year Guidance

  The company exceeded its full-year revenue targets and achieved the top end of its adjusted earnings-per-share guidance for 2025, reporting $701.2 million in net sales and $0.94 adjusted diluted EPS.

• Q4 2025 Performance

  Fourth quarter net sales increased 0.7% to $180.9 million. Adjusted diluted EPS was $0.29, compared to $0.43 in the prior year, while adjusted operating income was $22.6 million.

• 2026 Financial Outlook Provided

  Avanos Medical expects 2026 net sales to be between $700 million and $720 million, with adjusted diluted earnings per share projected to be between $0.90 and $1.10.

• Strategic Progress and Debt Reduction

  The company achieved 6% organic growth in strategic segments for the full year and reduced net debt to $10.7 million. Transformation initiatives are expected to deliver $15 to $20 million in incremental annualized savings by the end of 2026.

auto_awesomeAnalysis

Avanos Medical, Inc. reported its fourth quarter and full-year 2025 financial results, notably exceeding full-year revenue and achieving the top end of its full-year adjusted earnings-per-share guidance. This performance, following the 2025 estimates provided in January, demonstrates the company's ability to meet its internal targets. While adjusted operating profit and EBITDA for the full year 2025 were lower compared to 2024, the company made significant progress in reducing its net debt and advancing transformation initiatives expected to yield substantial annualized savings by the end of 2026. The 2026 outlook projects relatively stable net sales and adjusted diluted EPS, indicating a focus on consistent performance and operational efficiency rather than aggressive growth.